AzTrials
AzTrials

Lower Respiratory Tract InfectionsNCT07416266

Lower Respiratory Tract Infections Managed in Primary Care in France

An observational study of Lower Respiratory Tract Infections and Community Acquired Pneumonia (CAP), run by Hôpital Raymond Poincaré.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

Primary aim: To describe participant characteristics at the time of the index lower respiratory tract infection (LRTI) episode in adults managed in primary care in France, using anonymized electronic health records from routine clinical practice between January 2015 and December 2024. Read more about this study

Who is it for?
Ages 18 years and older
How many people
230,066 participants
Where
No sites listed yet
Study dates
1 Jan 2015to 9 Jan 2026
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Study population: Adult patients (≥18 years) with a recorded episode of community-acquired lower respiratory tract infection (LRTI) in French primary care between January 1, 2015 and December 31, 2024, identified from anonymized electronic health records in the THIN France database. Patients were required to have at least 12 months of prior medical history before the index episode.

Who may be able to join

  • Age ≥18 years
  • Recorded diagnosis of community-acquired lower respiratory tract infection in primary care between Jan 1, 2015 and Dec 31, 2024
  • At least 12 months of medical history available before the index consultation

Who cannot join

  • Age <18 years
  • Less than 12 months of medical data before index date

About this study

Official title: Lower Respiratory Tract Infections Managed in Primary Care: A 10-year Nationwide Real-World Data Warehouse Study

Primary aim:

To describe participant characteristics at the time of the index lower respiratory tract infection (LRTI) episode in adults managed in primary care in France, using anonymized electronic health records from routine clinical practice between January 2015 and December 2024.

Read more

Secondary aims:

To describe and quantify patterns of antibiotic prescribing (rate, type, and duration of treatment) and short-term outcomes, including LRTI-related reconsultations and severe complications within 30 days after the index consultation.

The overall objective is to better characterize real-world management and outcomes of lower respiratory tract infections in primary care and to identify potential areas for improving quality of care and optimizing antibiotic stewardship.

Read the detailed description

Lower respiratory tract infections are a frequent reason for consultation and antibiotic prescribing in primary care. However, nationally representative data describing real-world management in routine practice remain limited in France.

This nationwide retrospective observational study uses anonymized electronic health records from the THIN® France database, a large primary care data warehouse collecting routinely recorded clinical data from general practitioners. The study includes adults aged 18 years and older with a recorded episode of community-acquired lower respiratory tract infection between January 2015 and December 2024.

Each participant contributes a single index episode and is followed for 30 days to assess short-term outcomes. The study period allows the evaluation of management practices over a 10-year timeframe in routine ambulatory care.

The main objective is to describe patients characteristics and real-world management of lower respiratory tract infections in primary care, with a focus on patterns of care, treatment strategies, and short-term outcomes. This study is based exclusively on previously collected anonymized data and does not involve any intervention or change in patient care.

By providing a large-scale overview of routine practice, the study aims to improve understanding of current management approaches and identify potential areas for optimizing antibiotic use in primary care.

Keywords
Primary Care, Antimicrobial Stewardship, Electronic Health Records
Medical subject headings
Community-Acquired Pneumonia, Bronchitis, Influenza, Human

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

Study groups in NCT07416266
Study groupRoleWhat they receive
Antibiotic-Treated LRTIAdults with a recorded community-acquired lower respiratory tract infection (LRTI) in primary care in France between January 2015 and December 2024 whose index episode was associated with an antibiotic prescription during routine care. No intervention was assigned by the study.
Non-Antibiotic-Treated LRTIAdults with a recorded community-acquired lower respiratory tract infection (LRTI) in primary care in France between January 2015 and December 2024 whose index episode was not associated with an antibiotic prescription during routine care. No intervention was assigned by the study.

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Participant Characteristics at Index LRTI Episode

    Descriptive summary of participant characteristics at the index lower respiratory tract infection episode, including age, sex, body mass index, smoking status, alcohol use, comorbidities, and vaccination status, overall and by antibiotic exposure group.

    Measured: Index consultation

Secondary outcomes (5)
  1. Antibiotic Prescribing Rate

    Proportion of participants with an antibiotic prescription at the index episode, stratified on LRTI type

    Measured: Index consultation

  2. Type of Antibiotics Prescribed for Antibiotic-treated LRTIs

    Distribution of antibiotic classes prescribed at the index episode.

    Measured: Index consultation

  3. Duration of Antibiotic Treatment for Antiobiotic-treated LRTIs

    Duration of antibiotic treatment prescribed for the index episode.

    Measured: Index consultation

  4. 30-Day LRTI-Related Reconsultation Rate

    Proportion of participants with a follow-up consultation related to LRTI within 30 days.

    Measured: 30 days

  5. 30-Day Severe Complication Rate After LRTI

    Occurrence of Sepsis/septic shock, Pleural effusion, Lung abscess, Acute respiratory distress syndrome (ARDS) within 30 days after the index episode.

    Measured: 30 days

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted18 Feb 2026
  2. Study start1 Jan 2015
  3. Primary completion31 Dec 2024
  4. Study completion9 Jan 2026

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Retrospective
Enrolment
230,066 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07416266
Sponsor's protocol ID
LRTI-20152024
Status last verified
Feb 2026
First submitted
10 Feb 2026
Last updated
18 Feb 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No: Individual participant data come from an anonymized database with legal and contractual restrictions.

Questions about this trial

What is this clinical trial studying?

An observational study of Lower Respiratory Tract Infections and Community Acquired Pneumonia (CAP), run by Hôpital Raymond Poincaré.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 3 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 18 Feb 2026. Status can change between updates, so confirm with the study contact before making plans.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Participant Characteristics at Index LRTI Episode (time frame: Index consultation). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 18 Feb 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in